Not a Member?
Email this page
Send the page ""
to a friend, relative, colleague or yourself.
Separate multiple email address with a comma
We do not record any personal information entered above.
Thank you. Your email has been sent.
Blood Coagulation Factors
Antihemophilic factor for the treatment of bleeding episodes in adults with acquired hemophilia AGenetically engineered in baby hamster kidney (BHK) cell linePorcine factor VIII antibodies can develop
OBIZUR Intravenous Inj Pwd F/Sol
200 units/kg IV initially; initial dosing less than 200 units/kg has been associated with lack of efficacy. The subsequent dose, frequency, and duration of treatment depend on the severity of the factor VIII deficiency, the location and extent of bleeding, and the patient's clinical condition. Doses may be administered every 4 to 12 hours based on clinical response and measured factor VIII concentration. For minor and moderate bleeding (e.g., superficial muscle without neurovascular compromise, and joint), the circulating factor VIII concentration required is 50% to 100% of normal. For major bleeding (e.g., moderate to severe intramuscular bleeding, retroperitoneal, gastrointestinal, intracranial), the circulating factor VIII concentration required is 100% to 200% of normal to treat an acute bleed and 50% to 100% of normal after the acute bleed is controlled, if needed. Plasma concentration of factor VIII should not exceed 200% of normal or 200 units/dL. Safety and efficacy has not been established in patients with a baseline anti-porcine factor VIII inhibitor titer of more than 20 Bethesda Units (BU).
Specific maximum dosage information is not available. Individualize dosage based on the severity of the factor VIII deficiency, the location and extent of bleeding, and the patient’s clinical condition.
Safety and efficacy have not been established.
Specific guidelines for dosage adjustments in hepatic impairment are not available; it appears that no dosage adjustments are needed.
Specific guidelines for dosage adjustments in renal impairment are not available; it appears that no dosage adjustments are needed.
Factor VIII activity is expressed in units. Potency values are determined by a 1-stage clotting assay.Each single-use vial nominally contains 500 units per vial. The exact recombinant porcine factor VIII potency in units is stated on each vial.Plasma factor VIII concentrations can be monitored using a 1-stage clotting assay.
Visually inspect parenteral products for particulate matter and discoloration prior to administration whenever solution and container permit. The solution should be clear and colorless. Do not administer if particulate matter or discoloration are observed.
ReconstitutionUse aseptic technique throughout the entire reconstitution process.Allow vial of antihemophilic factor porcine sequence and prefilled diluent syringe (provided) to reach room temperature.Peel back the cover of the vial adapter package, taking care not to touch the Luer-lock (tip) in the center of the vial adapter. Do not remove the vial adapter from the plastic package.Place the vial adapter package on a clean surface with the Luer-lock pointing up.Snap off the tamper-resistant cap of the prefilled syringe.While firmly holding the vial adapter package, connect the prefilled syringe to the vial adapter by pushing the syringe tip down onto the Luer-lock in the center of the vial adapter. Turn clockwise until the syringe is secured. Do not over tighten.Remove plastic package.Place the antihemophilic factor porcine sequence vial on a clean, flat, hard surface. Place the vial adapter over the vial and firmly push the filter spike of the vial adapter through the center of the antihemophilic factor porcine sequence vial's rubber circle until the clear plastic cap snaps onto the vial.Push the plunger down to slowly inject all the diluent from the syringe into the vial.Gently swirl, in a circular motion, the antihemophilic factor porcine sequence vial without removing the syringe until all of the powder is fully dissolved.With 1 hand, hold the vial and adapter, and with the other hand firmly grasp the barrel of the prefilled syringe and in a counterclockwise motion, unscrew the syringe from the vial adapter.Storage: Use the reconstituted solution within 3 hours after reconstitution when stored at room temperature. Intermittent IV infusionOnce all vials have been reconstituted, attach a large syringe to the vial adapter by gently pushing the syringe tip down onto the Luer-lock in the center of the vial adapter, turning clockwise until it is securely in place.Invert the vial; push the air in the syringe into the vial and withdraw the reconstituted solution into the syringe.Unscrew the large syringe counterclockwise from the vial adapter, and repeat this process for all reconstituted vials until the total volume to be administered is reached.Do not administer in the same tubing with other medications.Administer intravenously at a rate of 1 to 2 mL/minute.
OBIZUR:- Discard product if it contains particulate matter, is cloudy, or discolored- Discard unused portion. Do not store for later use.- Do not freeze- Protect from light- Reconstituted product should be used within 3 hours- Refrigerate (between 36 and 46 degrees F)- Store in original container
Antihemophilic factor, porcine sequence, recombinant is contraindicated in patients who have had life-threatening hypersensitivity reactions to antihemophilic factor, porcine sequence, recombinant or its components, including trace amounts of hamster proteins (hamster protein hypersensitivity).
Consider testing for the presence of anti-recombinant porcine factor VIII inhibitors (anti-rpFVIII antibodies) before treatment initiation with antihemophilic factor, porcine sequence, recombinant. If anti-rpFVIII antibodies are detected after treatment initiation, use factor VIII concentrations to determine whether to continue treatment with antihemophilic factor, porcine sequence, recombinant. Monitor patients for the development of inhibitory antibodies using a Nijmegen Bethesda inhibitor assay and use Bethesda Units (BU) to report inhibitor concentrations. Suspect the presence of anti-porcine factor VIII antibody if plasma factor VIII concentrations fail to increase as expected or if bleeding is not controlled after administration of antihemophilic factor, porcine sequence, recombinant. If there is a lack of efficacy and factor VIII inhibitors are suspected, consider discontinuing antihemophilic factor, porcine sequence, recombinant and initiating other therapeutic agents (e.g., factor VIII bypassing agent). Anamnestic reactions with rise in human factor VIII and/or recombinant factor VIII, porcine sequence inhibitors may also occur and result in lack of efficacy.
There are no data with antihemophilic factor, porcine sequence, recombinant use in pregnant patients to inform a drug-associated risk. Is it not known if antihemophilic factor, porcine sequence, recombinant can cause fetal harm if given during pregnancy or if it can affect reproduction capacity. Animal reproduction studies have not been conducted with antihemophilic factor, porcine sequence, recombinant.
There is no data regarding the presence of antihemophilic factor, porcine sequence, recombinant in human milk, the effect on the breast-fed child, or its effect on milk production. Consider the developmental and health benefits of breast-feeding along with the mother's clinical need for antihemophilic factor, porcine sequence, recombinant and any potential adverse effects on the breast-fed child from antihemophilic factor, porcine sequence, recombinant or the underlying maternal condition.
anaphylactoid reactions / Rapid / Incidence not knownangioedema / Rapid / Incidence not known
antibody formation / Delayed / 26.0-26.0hypotension / Rapid / Incidence not knowndyspnea / Early / Incidence not knownwheezing / Rapid / Incidence not known
pruritus / Rapid / Incidence not knownurticaria / Rapid / Incidence not known
Emicizumab: (Moderate) There is a possibility for hypercoagulability with concomitant use of emicizumab and antihemophilic factor VIII (recombinant) based on preclinical experiments. Factor VIIa, Recombinant: (Major) The risk of potential interaction between factor VIIa, recombinant and coagulation factor concentrates has not been adequately evaluated. Simultaneous administration of factor VIIa with prothrombin complex concentrates is not recommended due to the increased risk for thrombosis. Likewise, it would be prudent to consider the potential for thromboembolic complications with coadministration of factor VIIa, recombinant and recombinant antihemophilic factor, porcine sequence, and use caution if administered concomitantly.
Patients with acquired hemophilia A have normal factor VIII genes but develop autoantibodies (i.e., inhibitors) against endogenous factor VIII. The autoantibodies neutralize circulating human factor VIII, resulting in a deficiency of this procoagulant protein. Patients with acquired hemophilia A have a prolonged clotting time, measured by aPTT, a conventional in vitro test for biological activity of factor VIII. Administration of recombinant antihemophilic factor, porcine sequence temporarily replaces the inhibited factor VIII needed for effective hemostasis and normalizes the aPTT over the effective dosing period. However, factor VIII activity, not aPTT, should not be used as a measure of efficacy during treatment.
Antihemophilic factor, porcine sequence, recombinant is administered intravenously. Formal pharmacokinetic studies have not been conducted. The pharmacokinetics were studied in 3 patients with hemophilia A and a history of human factor VIII inhibitors receiving a single antihemophilic factor, porcine sequence, recombinant dose of 100 units/kg. Utilizing the one-stage clotting assay, the mean (standard deviation) for Cmax was 176 (88) units/dL, Tmax was 0.6 (0.03) hours, and half-life was 10.63 (0.77) hours. Affected CYP450 isoenzymes or drug transporters: none